In this exclusive video interview, James Del Rosso, DO, gets into the details of JAK inhibitors, explaining how they work and cutting through the hype around the treatments.
A retrospective cohort study published in the International Journal of American Academy of Dermatology investigated the possible association between atopic dermatitis and hidradenitis suppurativa.
A study published in Pediatric Dermatology sought to investigate whether an educational handbook could improve atopic dermatitis (AD) symptoms, caregiver confidence in AD management skills, and AD-related quality-of-life.
Investigators said that patient-reported outcomes from the 2 abrocitinib groups showed greater efficacy than the dupilumab and placebo groups.
The potential of JAK inhibitors and other emerging medications could answer demand for more treatment options for these challenging skin conditions. Read down below.
Ruxolitinib meets primary and secondary endpoints in phase 3 TRuE-V clinical trial program.
Experts put forth their top pearls to help better take care of patients. Here’s what they said.
In this video interview, Mark Lebwohl, MD, explains why topicals for inflammatory conditions are vital for treatment.
In this video interview, Fatima Khan, MD, discusses how atopic dermatitis can be detrimental to pediatric patients sleep, how the condition can change as the patient gets older, and more.
In a session at ACAAI’s Annual Scientific Meeting, David R. Weldon, MD, FACAAI, FAAAI, demonstrates punch biopsies for allergists and discusses the importance of knowing when to collaborate with dermatologists.